

Disclosure pursuant to article 26a WpHG as per March 30, 2012

Pursuant to article 26a WpHG, BB Biotech AG, Vordergasse 3, 8200 Schaffhausen, Switzerland, hereby announces that the total voting rights at the end of March 2012 amounted to 14 762 250.

The new number of voting rights is effective as of March 1, 2012.

For further information please contact:

Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht / Zurich
Thomas Egger, Tel. +41 44 267 67 00.

Company profile

BB Biotech invests in companies in the fast growing market of biotechnology and is one of the world's largest investors in this sector with around CHF 1.2 bn in assets under management. BB Biotech is listed in Switzerland, Germany and Italy. Its investments are focused on listed companies that are developing and commercializing novel medical treatments and cures. BB Biotech's investment selection process is guided by the fundamental research and analysis of physicians and molecular biologists. Its Board of Directors has many years of experience in industry and science.